产品号 #100-0785_C
cGMP，人T细胞激活和扩增试剂
总览
无需使用磁珠、饲养层细胞或抗原，即可实现强劲的人T细胞激活与扩增。
该产品的温和激活刺激能确保T细胞的高活率，激活后的细胞可在ImmunoCult™-XF（按cGMP相关法规与指南生产的高性能扩增培养基）中进一步扩增。ImmunoCult™人CD3/CD28/CD2 T细胞激活剂由可溶性抗体复合物组成，能结合并交联CD3、CD28及CD2细胞表面配体，为T细胞培养与激活提供必需的关键信号与共刺激信号。
ImmunoCult™人CD3/CD28/CD2 T细胞激活剂专为细胞治疗临床研究应用设计，根据USP<1043>和/或PH. EUR. 5.2.12的框架标准，可作为辅助材料（AM）使用。STEMCELL可协助您将该试剂在获批的新药研究（IND）申请、生物制品许可申请（BLA）或临床试验申请（CTA）中申报作为辅助材料（AM）。点击此处进一步了解我们如何支持您的法规需求。
包含
• Anti-human CD3 monospecific antibody complex
• Anti-human CD28 monospecific antibody complex
• Anti-human CD2 monospecific antibody complex
• Phosphate buffered-saline (PBS)，containing 0.02% TWEEN® 20
亚型
添加剂
细胞类型
T 细胞，T 细胞，CD4+，T 细胞，CD8+
种属
人
应用
激活，细胞培养，扩增
品牌
ImmunoCult
研究领域
癌症，免疫，细胞治疗开发
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (6)
Publications (1)
Pharmacological Inhibition of MALT1 Ameliorates Autoimmune Pathogenesis and Can Be Uncoupled From Effects on Regulatory T-Cells. Frontiers in immunology 2022
Abstract
MALT1 forms part of a central signaling node downstream of immunoreceptor tyrosine-based activation motif (ITAM)-containing receptors, across a broad range of immune cell subsets, and regulates NF-$\kappa$B driven transcriptional responses via dual scaffolding-protease activity. Allosteric inhibition of MALT1 activity has demonstrated benefit in animal models of inflammation. However, development of MALT1 inhibitors to treat autoimmune and inflammatory diseases (A&ID) has been hindered by reports linking MALT1 inhibition and genetic loss-of-function to reductions in regulatory T-cell (Treg) numbers and development of auto-inflammatory syndromes. Using an allosteric MALT1 inhibitor, we investigated the consequence of pharmacological inhibition of MALT1 on proinflammatory cells compared to regulatory T-cells. Consistent with its known role in ITAM-driven responses, MALT1 inhibition suppressed proinflammatory cytokine production from activated human T-cells and monocyte-derived macrophages, and attenuated B-cell proliferation. Oral administration of a MALT1 inhibitor reduced disease severity and synovial cytokine production in a rat collagen-induced arthritis model. Interestingly, reduction in splenic Treg numbers was less pronounced in the context of inflammation compared with na{\{i}}ve animals. Additionally in the context of the disease model we observed an uncoupling of anti-inflammatory effects of MALT1 inhibition from Treg reduction with lower systemic concentrations of inhibitor needed to reduce disease severity compared to that required to reduce Treg numbers. MALT1 inhibition did not affect suppressive function of human Tregs in vitro. These data indicate that anti-inflammatory efficacy can be achieved with MALT1 inhibition without impacting the number or function of Tregs further supporting the potential of MALT1 inhibition in the treatment of autoimmune disease."
更多信息
| Species | Human |
|---|---|
| Contains | • Anti-human CD3 monospecific antibody complex • Anti-human CD28 monospecific antibody complex • Anti-human CD2 monospecific antibody complex • Phosphate buffered-saline (PBS), containing 0.02% TWEEN® 20 |
相关产品
-
ImmunoCult™ 人CD3/CD28 T细胞激活剂cGMP，人T细胞激活扩增试剂
-
ImmunoCult™ XF培养基cGMP，无血清和无异种成分培养基，用于人T细胞扩增
THIS PRODUCT IS MANUFACTURED AND TESTED FOLLOWING RELEVANT CGMPs UNDER A CERTIFIED QUALITY MANAGEMENT SYSTEM. PRODUCT IS FOR INVESTIGATIONAL OR RESEARCH USE. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
